Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients with T2DM

Trial Identifier: D1690L00149
Sponsor: AstraZeneca
Start Date: March 2024
Primary Completion Date: April 2025
Study Completion Date: June 2025
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100020
CN Beijing, CN, 100076
CN Beijing, CN, 102218
CN Beijing, CN, 100050
CN changsha, CN, 410005
CN Chengdu, CN, 610072
CN Chongqing, CN, 402260
CN Chuxiong, CN, 675000
CN Dalian, CN, 116001
CN Dingzhou, CN, 562100
CN Fuyang, CN, 236400
CN Guangzhou, CN, 510515
CN GUANGZHOU, CN, 510180
CN Guiyang, CN, 550044
CN Hefei, CN, 230012
CN Jiangyin, CN, 214400
CN Jiyuan, CN, 459003
CN Kunming, CN, 650032
CN Nanchang, CN, 330006
CN nanning, CN
CN Nantong, CN, 226001
CN Panjin, CN, 124000
CN Qingdao, CN, 266200
CN Quanzhou, CN, 362000
CN rui'an, CN, 325200
CN Shenzhen, CN, 518101
CN Suzhou, CN, 215500
CN Taiyuan, CN, 030001
CN Tianjin, CN, 300134
CN Wei Fang, CN, 261035
CN Wenzhou, CN, 325000
CN Wuhan, CN, 430010
CN Yibin, CN, 610500
CN Zhengzhou, CN, 450052
CN Zhuji, CN, 311899